Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WOK
WOK logo

WOK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.300
Open
1.290
VWAP
1.28
Vol
17.02K
Mkt Cap
2.21M
Low
1.260
Amount
21.79K
EV/EBITDA(TTM)
--
Total Shares
1.72M
EV
7.34M
EV/OCF(TTM)
1.17
P/S(TTM)
0.00
Work Medical Technology Group Ltd is a holding company mainly engaged in the manufacturing of medical devices. The Company's main products include medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, and other Class I disposable medical devices, disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kit, oxygen face masks, anesthesia masks, laryngoscope blades, yankauer suction sets, nasal oxygen cannulas, and other Class II disposable medical devices, KN95 masks, filtering half mask, and other medical devices, as well as medical innovative devices and equipment, such as visualized prostatic dilatation catheter. The Company principally conducts its businesses in domestic and overseas markets, such as Asia, Africa, Europe, North America, South America, and Oceania.
Show More

Events Timeline

(ET)
2025-12-29
09:40:00
WORK Medical Technology Signs Exclusive Distribution Agreement with Shanghai Benke
select
2025-12-29
09:10:00
WORK Medical Technology Subsidiary Receives Approval for AI Blood Cell Analyzer
select
2025-12-26 (ET)
2025-12-26
20:00:00
Work Medical Technology Group Ltd Trading Halted, News Pending
select
2025-12-10 (ET)
2025-12-10
09:40:00
Work Medical Technology Group Ltd Trading Resumes
select
2025-12-10
09:40:00
Work Medical Technology Group Ltd Trading Halted Due to Volatility
select
2025-12-03 (ET)
2025-12-03
15:40:00
Work Medical Technology Group Ltd Trading Resumes
select
2025-12-03
15:30:00
Work Medical Technology Group Ltd Trading Halted Due to Volatility
select
2025-11-04 (ET)
2025-11-04
09:06:23
WORK Medical's Neologics Secures $114,000 Service Agreement
select
2025-10-21 (ET)
2025-10-21
09:06:22
WORK Medical to Invest $1 Million in Equity in Neologics Bioscience
select

News

Newsfilter
7.5
05-01Newsfilter
WORK Medical Recognized as Vice President Unit of Hong Kong Web3.0 Association
  • Industry Leadership: WORK Medical has been awarded the Vice President Unit certification by the Hong Kong Web3.0 Standardization Association, underscoring its growing leadership in the tokenization of medical assets and data, which is expected to enhance the company's influence in the digital healthcare economy.
  • Whitepaper Release: At the Web3.0 Standardization and Globalization Summit in Hong Kong, WORK Medical released the Asset Tokenization Whitepaper, which provides a structured framework for global standardization at the intersection of medical devices and Web3.0, highlighting the company's significant role in industry standard development.
  • Advancement of A2A Payments: The company is advancing the implementation of A2A autonomous payment protocols aimed at enabling cross-border value exchange through stablecoins, which is expected to improve transaction efficiency and reduce liquidity costs for medical assets, facilitating their digital transformation.
  • Strategic Transformation: Management stated that WORK Medical is transforming from a traditional supplier of medical consumables to a builder of next-generation medical infrastructure, focusing on leveraging AI and blockchain technology to drive a sustainable healthcare economy and create long-term digital value.
Benzinga
9.5
02-06Benzinga
Roblox Reports Quarterly Earnings Exceeding Expectations
  • Quarterly Losses in Line: Roblox reported a quarterly loss of $0.45 per share, aligning with analyst expectations, which indicates stability in financial management despite ongoing challenges.
  • Revenue Beats Expectations: The quarterly revenue reached $2.22 billion, surpassing the analyst consensus estimate of $2.05 billion and significantly up from $1.36 billion in the same period last year, showcasing the company's success in user growth and monetization.
  • Stock Price Surge: Roblox shares jumped 14.3% to $69.24 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
  • Market Dynamics Impact: The release of this earnings report could influence the stock performance of other related companies, particularly in the gaming and tech sectors, demonstrating market confidence in the industry.
Benzinga
8.5
01-02Benzinga
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
  • Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
  • Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
  • Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
  • Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
Benzinga
8.5
2025-12-31Benzinga
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
  • Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
  • Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
  • Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
  • Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
Benzinga
8.5
2025-12-30Benzinga
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
  • Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
  • Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
  • Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
  • Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
Benzinga
3.5
2025-12-29Benzinga
WORK Medical Secures Approval for AI Blood Cell Analyzer, Manufacturing Set for 2026
  • Product Approval: The Hunan Provincial Medical Products Administration has approved WORK Medical's AI-powered automated human blood cell morphology analyzer for manufacturing, scheduled to begin in the first half of 2026, which will enhance efficiency and accuracy in microscopic examinations, thereby strengthening the company's competitive position in the medical device market.
  • Sales Agreement Signed: The company has entered into a one-year exclusive distribution agreement with Shanghai Benke Medical Technology, establishing a minimum annual sales target of approximately $1.4 million, which will facilitate the promotion and distribution of the product in East China throughout 2026, further expanding market share.
  • Prepayment Assurance: Shanghai Benke has prepaid a performance bond of $142,300, which will be deducted from the final payment or refunded without interest upon achieving the sales target, ensuring the feasibility of the sales goal and stabilizing the company's cash flow.
  • Broad Market Prospects: CEO Shuang Wu indicated that with continuous AI algorithm iteration, the product is expected to become standard equipment in tertiary hospitals and primary-care laboratories, supporting early screening of blood disorders and quality control, while optimizing labor costs, showcasing significant market potential.

Valuation Metrics

The current forward P/E ratio for WORK Medical Technology Group Ltd (WOK.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess WORK Medical Technology Group Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks that will explode in next 30 days
Intellectia · 640 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Month Price Change Pct: >= $0.00One Month Rise Prob: >= 70One Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
PRCH logo
PRCH
Porch Group Inc
1.23B
ROMA logo
ROMA
Roma Green Finance Ltd
396.70M
MCBS logo
MCBS
Metrocity Bankshares Inc
921.13M
UA logo
UA
Under Armour Inc
2.59B
INNV logo
INNV
InnovAge Holding Corp
1.08B
DOCN logo
DOCN
DigitalOcean Holdings Inc
15.94B
stock bullish for a month
Intellectia · 644 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Ema 20: >= 0Ema 60: >= 0One Month Rise Prob: >= 70One Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
WOK logo
WOK
WORK Medical Technology Group Ltd
2.40M
SABS logo
SABS
SAB Biotherapeutics Inc
258.61M
GIII logo
GIII
G-III Apparel Group Ltd
1.31B
IRIX logo
IRIX
IRIDEX Corp
18.27M
CCO logo
CCO
Clear Channel Outdoor Holdings Inc
1.19B
VTMX logo
VTMX
Vesta Real Estate Corporation SAB de CV
3.03B

Whales Holding WOK

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is WORK Medical Technology Group Ltd (WOK) stock price today?

The current price of WOK is 1.28 USD — it has decreased -2.29

What is WORK Medical Technology Group Ltd (WOK)'s business?

Work Medical Technology Group Ltd is a holding company mainly engaged in the manufacturing of medical devices. The Company's main products include medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, and other Class I disposable medical devices, disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kit, oxygen face masks, anesthesia masks, laryngoscope blades, yankauer suction sets, nasal oxygen cannulas, and other Class II disposable medical devices, KN95 masks, filtering half mask, and other medical devices, as well as medical innovative devices and equipment, such as visualized prostatic dilatation catheter. The Company principally conducts its businesses in domestic and overseas markets, such as Asia, Africa, Europe, North America, South America, and Oceania.

What is the price predicton of WOK Stock?

Wall Street analysts forecast WOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WOK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is WORK Medical Technology Group Ltd (WOK)'s revenue for the last quarter?

WORK Medical Technology Group Ltd revenue for the last quarter amounts to NaN USD, decreased

What is WORK Medical Technology Group Ltd (WOK)'s earnings per share (EPS) for the last quarter?

WORK Medical Technology Group Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does WORK Medical Technology Group Ltd (WOK). have?

WORK Medical Technology Group Ltd (WOK) has 238 emplpoyees as of May 11 2026.

What is WORK Medical Technology Group Ltd (WOK) market cap?

Today WOK has the market capitalization of 2.21M USD.